header-news

Latest News

IMPORTANT NOTIFICATION: Zantac (Ranitidine) Recall

October 3, 2019

Dear Doctor, Aspen Pharmacare Australia Pty Ltd, in consultation with the Therapeutic Goods Administration (TGA), is conducting a retail level recall of Zantac (ranitidine) tablets, effervescent tablets, syrup and ampoules. The TGA has not requested that a Dear Doctor letter be sent for this retail level product recall. We are informing you as the potentially…

Read More >>

ANNOUNCEMENT – Aspen Pharma – QUARANTINE STATUS LIFTED and URGENT PRODUCT DEFECT CORRECTION – ENDONE oxycodone hydrochloride 5mg tablet pack

July 30, 2019

Aspen Pharma is lifting the current retail level quarantine and undertaking a product defect correction for one batch Endone tablets -Batch CW612. We are contacting you as our records indicate that units from this particular batch may have been supplied to your organisation. Download Letter Download Letter – TGA

Read More >>

ANNOUNCEMENT – Aspen Pharmacare – URGENT MEDICINE RECALL FOR PRODUCT CORRECTION of SPAN K (potassium chloride) 600mg Tablets TGA reference: RC-2017-RN-00300-1

April 21, 2017

The bottle cap on Span K (potassium chloride) 600mg tablets is not child resistant. Apsen Pharmacare is conducting a recall for product correction to replace the current plain white cap with an enclosed child resistant cap. Future stock will include a child resistant cap.

Read More >>

ANNOUNCEMENT – Aspen AstraZeneca Anaesthetics Portfolio Agreement

June 10, 2016

Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca AB and AstraZeneca UK (“AstraZeneca”) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca’s global (excluding the USA) anaesthetics portfolio (“the Transaction”).

Read More >>

ANNOUNCEMENT: Divestment of portfolio to Strides

September 1, 2015

As of 1 September 2015 Aspen has divested to Strides (Australia) Pharma Pty Ltd a portfolio of its products commercialised in Australia and New Zealand. The range primarily includes the Aspen Generics Product Portfolio and business, including the Chemists’ Own range. Strides, to be called Arrow Pharmaceuticals in Australia, has a core focus on generic product development, and with its strong manufacturing and procurement capabilities has better opportunities to promote and grow this portfolio.

Read More >>

WINNER Aspen Values Award – JOHN SEGEDIN, Warehouse Leading Hand, Operations, Dandenong

November 11, 2014

It is with great pleasure and pride we communicate that at the 2014 Aspen Global Recognition Awards held in Johannesburg South Africa on Friday 7 November, John Sedgedin was announced the winner of the Aspen Values Award.

 

Read More >>

S26 Original Progress Withdrawal – Update

July 16, 2014

Aspen Nutritionals takes product safety very seriously and we are in the process of investigating the issue. We have not received any further complaints of this nature.

Read More >>

Voluntary Withdrawal of S-26 Original Progress Formula, Batch Number 40727482A2

July 15, 2014

Aspen Nutritionals Australia Pty Ltd is very concerned that a customer has reported finding a lizard in a tin of S-26 Original Progress formula, and is voluntarily withdrawing the affected batch number 40727482A2 while it investigates the issue.  No other products or batches are affected, and consumers can continue to use these with confidence.

Read More >>

Ferinject® (ferric carboxymaltose) 10ml (500mg) available on the Pharmaceutical Benefits Scheme (PBS) from the 1st June, 2014

June 1, 2014

Aspen Australia is pleased to advise that from the 1st June, 2014 Ferinject® (ferric carboxymaltose) 10ml (500mg) is available on the Pharmaceutical Benefits Scheme (PBS) as a drug for iron deficiency anaemia.# Ferinject® (ferric carboxymaltose) is available in Australia for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests.

Read More >>

Honorary Doctor of Commerce Degree conferred on Stephen Saad

April 16, 2014

Port Elizabeth – The Nelson Mandela Metropolitan University (NMMU) today conferred the degree of Doctor of Commerce (honoris causa) on Stephen Saad, Aspen Group Co-Founder and Chief Executive. Chancellor of the NMMU, Santie Botha said, ‘’It is an honour for NMMU to confer this honorary degree on Stephen Saad. His vision and drive in the world of business is inspiring and as NMMU we acknowledge the turn-around he orchestrated in a Port Elizabeth-based company that provides jobs to people in an economically struggling province’’.

Read More >>